Takeda Pharmaceutical: Maintain Hold Despite Strong Performance in 2025-2026

miércoles, 25 de marzo de 2026, 5:26 pm ET1 min de lectura
TAK--

Takeda Pharmaceutical has performed better than expected in 2025-2026, prompting a review of previous predictions. Despite a "wrong call", the company has shown positive growth, leading to a "hold" rating despite initial expectations of flat or negative performance.

Takeda Pharmaceutical: Maintain Hold Despite Strong Performance in 2025-2026

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios